Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 434-430-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 2000-04-07 to 2000-12-06
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 000
- Report date:
- 2000
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 1995
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: CD® (SD) IGS BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles river (UK) Limited, Margate, Kent, England
- Age at study initiation: 39 to 43 days
- Weight at study initiation: 184 to 214g for males and 145 to 182g for female
- Fasting period before study: no
- Housing: Five of one sex per cage. The cages were made of a stainless steel body with a stainless steel mesh lid and floor.
- Diet (e.g. ad libitum): ad libitum except overnight before routine blood sampling. Rat and Mouse n°1 Maintenance Diet (Special Diets Services Limited, Witham, Essex, England)
- Water (e.g. ad libitum): ad libitum, via polycarbonates bottles fitted with sipper tubes.
- Acclimation period: 13 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-25°C
- Humidity (%): 40-70%
- Air changes (per hr): 15 air changes per hour
- Photoperiod (hrs dark / hrs light): 12-hour light, 12-hour dark cycle
IN-LIFE DATES: No data
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 1% w/v methylcellulose in purified water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test substance was prepared for administration as a series of graded suspensions in 1.0% w/v methylcellulose in purified water. The required amount of test material was weighed and transferred to a suitably sized mortar and ground using a pestle. A small amount of 1.0% methylcellulose was added to the mortar and test material mixed to a smooth paste. The remaining amount of 1.0% methylcellulose was added to give the require concentration and the suspension was mixed using a high-shear homogeniser to produce a homogenous suspension.
VEHICLE
- Justification for use and choice of vehicle (if other than water): homogeneous suspensions were obtained with 1.0% w/v methylcellulose in purified water as vehicle
- Concentration in vehicle: 1.5, 15 and 100 mg/ml
- Amount of vehicle (if gavage): 10 mL/kg bw/day
- Lot/batch no. (if required): nodata
- Purity: no data - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The results of the homogeneity assessment showed that at 1.5 and 100 mg/mL, E96096 was homogeneously distributed throughout the 1.0% methylcellulose formulations.
The mean concentrations of E96096 in formulations for dosing on Day 1 of treatment, ranged from 96.0 - 97.7 % of nominal concentrations and were considered satisfactory. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- 7 days/ week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 15 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
In a previously conducted seven-day repeated dose oral toxicity study, CD rats were dosed with 250, 500 or 1000 mg/kg bw /day of the test substance. There were no deaths. The appareance and behaviour of the animals were unaffected by treatment. Bodyweight gain, food consumption and food conversion efficiency were unaffected by treatment. There were no organ weight changes attributable to treatment with the test material and no macroscopic findings at necropsy. Dosages of 15, 150 and 1000 mg/kg were considered suitable for the subsequent 4-week study. - Positive control:
- None
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: twice daily
Animals were inspected at least wice daily for evidence of reaction to treatment or ill-health. Any deviations from normal were recorded at the time in respect of nature and severity, date and time of onset, duration and progress of the observed condition, as appropriate.
BODY WEIGHT: Yes
- Time schedule for examinations: each animal was weighed during the acclimatisation period, on the day that treatment commenced, weekly throughout the treatment period and before necropsy.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
The weight of food supplied to each animal, that remaining and an estimate of any spilled was recorded for each week throughout the treatment period. From these records, the mean consumption per animal was calculated for each cage.
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: on day 29
- Anaesthetic used for blood collection: isoflurane
- Animals fasted: Yes, overnight withdrawal of food
- How many animals: 40
- Parameters examined: Haematocrit (Hct), Haemoglobin concentration (Hb), Erythrocyte count (RBC), Mean cell haemoglobin (MCH), Mean cell haemoglobin concentration (MCHC), Mean cell volume (MCV), Total white cell count (WBC), Differential WBC count including Neutrophils (N), Lymphocytes (L), Eosinophils (E), Basophils (B), Monocytes (M), Large unstained cells (LUC), Platelet count (Plt), Prothrombin time (PTP) and Activated partial thromboplastin time (APTT).
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: on day 29
- Animals fasted: Yes, overnight withdrawal of food
- How many animals: 40
- Parameters examined: Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma-glutamyl transpeptidase activity (gGT), Total bilirubin (Bili), Urea, Creatinine (Creat), Glucose (Gluc), Total cholesterol (Chol), Triglycerides (Trig), Sodium (Na), Potassium (K), Chloride (Cl), Calcium (Ca), Inorganic phosphorus (Phos), Total protein (Total Prot) and Albumin (Alb).
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Before commencement of treatment and weekly during the study. the FOB was performed prior to dosing during the treatment period and at a similar time of day on each occasion.
- Dose groups that were examined: All groups
- Battery of functions tested:
=> in the hand and standard arena observations performed before commencement and during each week of treatment: ease of removal from cage, salivation, lacrimation, exophthalmos, piloerection, fur condition, vocalisation on handling, reactivity to handling, arousal, gait, grooming, palpebral closure, posture, activity counts, rearing count, tremors, twitches, convulsion, defecation, urination.
=> Reflexes and responses were recorded before commencement and during week 4 of treatment: approach response, touch response, auditory qtartle reflex, tail pinch response, righting reflex, body temperature, landing footsplay, grip strength, pupil closure reflex.
=> Motor activity was measured before commencement and during week 4 of treatment. Activity measurements were recorded for ten six-minutes periods (a total of one hour).
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
All animals were subject to a detailed necropsy. All external features and orifices were examined visually. Any abnormality in the appearance or size of any organ and tissue (external and cut surface) was recorded.
HISTOPATHOLOGY: Yes
The following tissues were examined for all study animals of Groups 1 (Control) and 4 (1000 mg/kg bw /day) sacrificed on completion of the 4-week treatment period:
Adrenals - cortex and medulla
Brain - cerebellum, cerebrum and midbrain
Femur with - longitudinal section including bone marrow
joint
Heart - included auricular and ventricular regions
Ileum - included Peyers patch , where possible
Kidneys - included cortex, medulla and papilla regions
Liver - section from each of the five major lobes
Lungs - section from two major lobes, including bronchi
Spinal cord - transverse and longitudinal section at the cervical level
Stomach - included keratinised, glandular and antrum in sections
Thyroid - included parathyroids in section where possible
Uterus - uterus section separate from cervix section - Statistics:
- For organ weights and bodyweight changes, homogeneity of variance was tested using Barlett's test. Whenever this was found to be statistically significant a Behrens-Fisher test was used to perform pairwisecomparisons, otherwise a Dunnett's test was used.
Inter-group differences in macroscopic pathology and histopathology were assessed using Fisher's Exact test.
For clinical pathology data, if the data consisted predominantly of one particular value (relative frequency of the mode exceeded 75%), the proportion of values diffrent from the mode was analysed (Fisher, 1950) followed by a test for a trend in proportion (Mantel, 1963). Otherwise, a test for heterogeneity of variance between treatments was applied (Barlett, 1937). If significant heterogeneity was found at the 1% level, a logarithmic transformation was tried to see if a more stable variance structure could be obtained. If no significant heterogeneity was detected (or if a satisfactory transformation was found) and more than two groups were being compared, group means were compared using William's test for a dose-related response (Williams, 1971-72), or if there was evidence for a non-monotonic response, Dunnett's test (Dunnett, 1955, 1964). For separate two-group comparisons, a Student's t test was used. If significant heterogeneity of variance was present (and could not be removed by a logarithmic transformation), groups were compared using Shirley's non-parametric test for a dose-related response (Shirley, 1977), or if there was evidence for a non-monotonic response, Dunn's test (Dunn, 1964). For separate two-group comparisons, a Wilcoxon rank sum test (Wilcoxon 1945) was used.
Unless stated, group mean values or incidences for the treated groups were not significantly different from those of the Controls (p>0.05).
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
There were no deaths and no clinical signs related to the treatment with the test material.
BODY WEIGHT AND WEIGHT GAIN
Bodyweight gain was considered to be unaffected by treatment.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
Food consumption was considered to be unaffected by treatment.
FOOD EFFICIENCY
Food conversion efficiency was considered to be unaffected by treatment.
HAEMATOLOGY
There were no haematologival changes which were considered to be related to treatment.
A few inter-group differences attained statistical significance but there were minor, seen in one sex only and were considered to have arisen by chance.
CLINICAL CHEMISTRY
No clinical chemistry changes which were considered to be related with treatment.
NEUROBEHAVIOUR
There were no inter-group differences in arena observations that were considered to be associated with treatment.
Landing footsplay and grip strength measurements showed some inter-group variation during week 4 of treatment and some differences achieved statistical significance. There were, however, no consistent trends and many of the differences were apparent before commencement of treatment, an association with treatment was therefore discounted.
Motor activity was unaffected by treatment.
ORGAN WEIGHTS
Organ weights were unaffected by treatment.
GROSS PATHOLOGY
Macroscopic examination of animals killed on completion of the treatment period did not reveal any treatment-related findings.
HISTOPATHOLOGY: NON-NEOPLASTIC
There were no microscopic findings which were attributable to treatment with the test material. All microscopic findings were considered to be incidental and of no toxicological importance.
Effect levels
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- The daily administration to CD rats of the test material, at dosages of 15, 150 and 1000 mg/kg/day for four weeks was not associated with any evidence of toxicity. The No-Observe-Effect Level (NOEL) is considered to be 1000 mg/kg bw/day .
- Executive summary:
In a sub-acute study performed according to OECD 407 guideline and in compliance with GLP, test material diluted in 1.0% methylcellulose in purified water was administered by oral gavage to three groups of rats (5/sex) at 15, 150 and 1000 mg/kg bw/day for four weeks. A control group received vehicle alone at the same volume-dosage (10 mL/kg bw/day).
There were no deaths and no clinical signs related to treatment, no evidence of neurotoxicity during the weekly functional battery test. Bodyweight, food consumption and food conversion efficiency were not affected by treatment. There were no haematological or blood chemistry changes related to treatment. Organ weights were unaffected by treatment and there were no macroscopic or microscopic findings which were attributable to the treatment with the test material.
The No-Observed-Effect Level (NOEL) was considered to be 1000 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies